"While the [Executive Order] does not immediately change regulations, it directs federal agencies to issue guidance, initiate rulemakings and deliver recommendations on a range of prescription drug issues. Key areas include reforming IRA implementation, especially the treatment of small molecule drugs under the 'pill penalty,' as well as expanding drug importation, improving pharmacy benefit manager (PBM) fee transparency, reevaluating hospital drug reimbursement and promoting access to discounted insulin and epinephrine."  MORE >>